Pentoxifylline and vitamin E treatment for prevention of radiation induced side effects in women with breast cancer

ISRCTN ISRCTN39143623
DOI https://doi.org/10.1186/ISRCTN39143623
Secondary identifying numbers Ptx-5
Submission date
11/10/2007
Registration date
30/10/2007
Last edited
06/07/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Eliabeth Kjellen
Scientific

Department of Oncology
Lund University Hospital
Lund
SE 221 85
Sweden

+46 (0)46 176661
elisabeth.kjellen@med.lu.se

Study information

Study designThe trial is randomised, single centre, placebo controlled, double-blinded, with a parallel study design. Randomisation is stratified for previous cytostatic treatment
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study acronymPtx-5
Study objectivesPrimary objective:
To investigate if pentoxifylline and vitamin E prevent radiation induced side effects measured as impaired shoulder mobility in women treated for breast cancer with radiotherapy to the axilla and breast.

Secondary objective:
To investigate if pentoxifylline and vitamin E prevent radiation-induced side effects measured as lymphoedema, and Late Effects Normal Tissue task force Subjective, Objective, Management, and Analytic (LENT-SOMA) breast score in women treated for breast cancer with radiotherapy to the axilla and breast.

Tertiary objective:
To investigate if pentoxifylline and vitamin E influence development of new Radiation-Induced Fibrosis (RIF) areas as measured with an impedance method and to investigate if pentoxifylline influence the plasma levels of Transforming Growth Factor-beta1 (TGF-beta1) in women treated for breast cancer with radiotherapy to the breast and axilla.
Ethics approval(s)Ethics approval received from Lund University Ethics Committee on the 8th December 2003 (ref: LU758-03).
Health condition(s) or problem(s) studiedBreast cancer
InterventionPatients will be included in the study one month after termination of radiotherapy. At that time all other active cancer treatment will be finished, except for anti-hormone treatment with tamoxifen, letrozol, anastrozole and exemestane that are allowed as concomittant medication in this study.

During the first visit the patients will be assessed for eligibility and given a screening number. They will be informed about the study and the purpose of it. After giving their informed consent the subjects will undergo a physical examination, and their medical history will be obtained. The inclusion and exclusion criteria will be checked and then the subject will be randomised to a treatment group and given a patient number.

There are two treatment groups in the study. Both groups have the same number of patients:
Group A: treated with pentoxifylline and vitamin E
Group B: treated with placebo and vitamin E

Pentoxifylline/placebo will be escalated to 400 mg three times daily. The vitamin E dose will be 100 mg three times daily. The patients will be treated for 12 months.
Intervention typeSupplement
Primary outcome measureShoulder mobility is assessed by a goniometer; axillary movement will be analysed first time when all 80 patients have finished the first year of medication.
Secondary outcome measures1. Lymphoedema, assessed by measurement of water displacement
2. LENT-SOMA breast score, assessed every 3 months during the year of medication, twice in year 2 and yearly for 3 years up to 5 years
3. Impedance measurement of RIF areas
4. Plasma TGF-beta1 levels, analysed as a separate part of the study when patients have been included for 1 year

Secondary endpoint will be analysed (blinded) after one year of medication. All patients will be followed for 5 years and the final analysis will be done when all patients have been followed for 5 years.
Overall study start date13/05/2004
Completion date10/05/2012

Eligibility

Participant type(s)Patient
Age groupAdult
SexFemale
Target number of participants80
Key inclusion criteria1. Women (no age limit) with breast cancer
2. Treated with axillary dissection, mastectomy or segmental resection of the breast, and radiotherapy to the breast and axilla
3. All active cancer treatment is terminated, except for anti-hormone treatment with tamoxifen, letrozol, anastrozole, and exemestane
4. Able to understand the nature of the trial and give written informed consent
Key exclusion criteria1. Known sensitivity to pentoxifylline or vitamin E
2. Disorders related to muscles or joints
3. Corticosteroid treatment during radiotherapy treatment
Date of first enrolment13/05/2004
Date of final enrolment10/05/2012

Locations

Countries of recruitment

  • Sweden

Study participating centre

Department of Oncology
Lund
SE 221 85
Sweden

Sponsor information

Lund University Hospital (Sweden)
Hospital/treatment centre

c/o Elisabeth Kjellen
Department of Oncology
Lund
SE 221 85
Sweden

+46 (0)46 176661
elisabeth.kjellen@med.lu.se
http://www.med.lu.se/english
ROR logo https://ror.org/012a77v79

Funders

Funder type

Research organisation

Swedish Cancer Society (Cancerfonden) (Sweden) (ref: 4981-B05-02XBC)
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
Swedish Cancer Society
Location
Sweden

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/09/2009 Yes No
BMC - Part of Springer Nature Springer Nature